奥洛兹美医疗 HALO 深 沪
等待开盘 07-03 09:30:00 美东时间
79.45
+2.440
+3.17%
华盛通- 最 高79.51
- 今 开77.85
- 成交量 155.82万股
- 最 低 77.54
- 昨 收 77.01
- 总市值 942.38万
- 52周最高 82.22
- 市盈率 静 31.07
- 换手率 1313.67%
- 52周最低 55.64
- 委 比 57.26%
- 总股本 0.00亿
- 历史最高 82.22
- 量 比 0.76
- 振 幅 2.56%
- 历史最低 3.86
- 每 手 1
- 风险率 5.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Halozyme Appoints David Ramsay as President Drug Delivery
SAN DIEGO, June 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of David Ramsay as President Drug Delivery, ...
07-01 04:02
As corporate profit margins remain elevated, these mid-caps stand out
With U.S. corporate profit margins remaining near historic highs, investors are increasingly focused on companies that have demonstrated an ability to consistently generate strong earnings and returns...
06-18 21:25
Halozyme Sees Little Royalty Impact From Medicare Drug Pricing Rule, Says CMS Proposal Should Not Hurt ENHANZE Partnerships
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the proposed rule for the Medicare Drug Price Negotiation Program ("Program") issued by the U.S. Centers for Medicare & Med...
06-15 18:14
Halozyme CEO Helen Torley disposes of USD 2.98 million in common shares
Halozyme CEO Helen Torley disposes of USD 2.98 million in common shares Halozyme CEO Helen Torley exercised stock options, acquiring 50,000 common shares at $12.07 from June 1-3, 2026. Torley sold 50,000 common shares over the same period at weighted average prices of $66.31-$69.69. Directly owned c
06-04 08:07
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings May 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including CAVA Group, Eagle Materials and Vertiv Holdings, on Wednesday. HIGHLIGHTS * CAVA Group Inc CAVA.N
05-20 15:07
美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
Halozyme Earnings Call Highlights Royalty-Fueled Growth
Halozyme Therapeutics (($HALO)) has held its Q1 earnings call. Read on for the ...
05-13 08:25
电话会总结 ｜ Halozyme(HALO)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Halozyme业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 总营收：3.77亿美元，同比增长42% - 特许权使用费收入：2.41亿美元，同比增长43%，主要由DARZALEX、VYVGART Hytrulo和PHESGO推动 **盈利能力：** - 调整后EBITDA：2.30亿美元，同比增长超过40% - 调整后EBITDA利润率：约61%（2.30亿/3.77亿） - Non-GAAP每股收益：1.60美元，同比增长44%（从1.11美元增至1.60美元） - GAAP每股收益：1.22美元，同比增长
05-12 12:02
Halozyme Therapeutics Affirms FY2026 Adj EPS Guidance of $7.75-$8.25 vs $8.09 Est; Affirms FY2026 Sales Guidance of $1.710B-$1.810B vs $1.760B Est
Halozyme Therapeutics (NASDAQ:HALO) affirms FY2026 Adj EPS guidance from $7.75-$8.25 to $7.75-$8.25 vs $8.09 analyst estimate. Affirms FY2026 sales outlook from $1.710 billion-$1.810 billion to $1.710 billion-$1.810
05-12 04:58
Halozyme Therapeutics Q1 Adj. EPS $1.60 Beats $1.53 Estimate, Sales $376.708M Beat $359.053M Estimate
Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $1.60 per share which beat the analyst consensus estimate of $1.53 by 4.58 percent. This is a 44.14 percent increase over earnings of $1.11 per share
05-12 04:03
